SIETES :: 92761 citas

Resultados de la búsqueda por HIPOTIROIDISMO REFINAR BÚSQUEDA

1.

Anónimo. Ginkgo biloba: to be avoided due to severe adverse effects. Prescrire Int 2019;28:155-6. [Ref.ID 103129]

2.

Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Ospina NS, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ 2019;365:14 de mayo. [Ref.ID 103122]

3.

Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rodevand L, Melle I, Andreassen OA, Molden E, Jönsson EG. Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. J Psychiatr Res 2018:25 de septiembre. [Ref.ID 102832]

4.

Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ 2018;360:k793. [Ref.ID 102549]

5.

Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ 2018;360:k714. [Ref.ID 102544]

6.

Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology 2017:5 de septiembre. [Ref.ID 102058]

7.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

8.

Anónimo. Drugs for hypothyroidism. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:147-50. [Ref.ID 99814]

9.

Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]

10.

Malhi GS. Lithium therapy in bipolar disorder: a balancing act?. Lancet 2015;386:415-6. [Ref.ID 99396]

11.

Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015;386:461-8. [Ref.ID 99217]

12.

Shlipak MG, Coresh J, Gansevoort RT. Cystatin C versus creatinine for kidney function-based risk. The authors reply. N Engl J Med 2013;369:2459. [Ref.ID 96682]

13.

Vandecasteele SJ, De Vriese AS. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458-9. [Ref.ID 96681]

14.

Cherney D, Maahs DM. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458. [Ref.ID 96680]

15.

Tavares Jr AR. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2457-8. [Ref.ID 96679]

16.

Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after vaccination of adolescent girls with quadrivalent human papillomavirus in Denmark and Sweden: cohort study. BMJ 2013;347:12. [Ref.ID 96429]

17.

Brotherton JML. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013;347:10. [Ref.ID 96427]

18.

Mrkobrada M, Hackam DG. Selective serotonin reuptake inhibitors and surgery: to hold or not to hold, that is the question: Comment on "Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery". JAMA Intern Med 2013;173:1082-3. [Ref.ID 95724]

19.

Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013;173:1075-81. [Ref.ID 95722]

20.

Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013;36:413-26. [Ref.ID 95664]